Medicare Enrolled

Dr. Parvez Khan, M.D.

Medical Oncology · Dearborn, MI
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
861 MONROE ST, Dearborn, MI 48124
3132740774
In practice since 2005 (20 years)
NPI: 1184615205 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Khan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khan? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Khan

Dr. Parvez Khan is a medical oncology specialist in Dearborn, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Khan performed 2,052 Medicare services across 666 unique beneficiaries.

Between the years covered by Open Payments, Dr. Khan received a total of $7,686 from 59 pharmaceutical and/or device companies across 353 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Khan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 33% volume in MI $7,686 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,052
Medicare services
Top 33% in MI for medical oncology
666
Unique beneficiaries
$88
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~103 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
1,234 $64 $150
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
324 $132 $250
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
275 $102 $200
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
164 $141 $300
New patient office visit, complex (60-74 min) 38 $172 $250
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
17 $73 $150
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$7,686
Total received (2018-2024)
Avg $1,098/year across 7 years
Top 33% in MI for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
59
Companies
353
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,566 (85.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,120 (14.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,920
2023
$2,067
2022
$1,668
2021
$672
2020
$87
2019
$112
2018
$160

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$411
Daiichi Sankyo Inc.
$233
ABBVIE INC.
$175
Janssen Biotech, Inc.
$173
PFIZER INC.
$166
Celgene Corporation
$145
Gilead Sciences, Inc.
$140
Genentech USA, Inc.
$120
GENZYME CORPORATION
$116
Exelixis Inc.
$99
SANOFI-AVENTIS U.S. LLC
$98
JAZZ PHARMACEUTICALS INC.
$92
Astellas Pharma US Inc
$91
E.R. Squibb & Sons, L.L.C.
$69
PharmaEssentia USA Corporation
$67
Eisai Inc.
$65
Tempus AI, Inc
$64
TerSera Therapeutics LLC
$56
Merck Sharp & Dohme LLC
$54
Takeda Pharmaceuticals U.S.A., Inc.
$54
EMD Serono, Inc.
$42
Incyte Corporation
$41
GlaxoSmithKline, LLC.
$40
AstraZeneca Pharmaceuticals LP
$35
Octapharma USA, Inc.
$33
SOBI, INC
$31
RECORDATI_RARE_DISEASES_INC.
$26
Kite Pharma, Inc.
$23
TAIHO ONCOLOGY, INC.
$23
Janssen Pharmaceuticals, Inc
$20
Lilly USA, LLC
$19
ARRAY BIOPHARMA INC
$18
Mirati Therapeutics, Inc.
$18
Stemline Therapeutics Inc.
$17
Dendreon Pharmaceuticals LLC
$16
SHIELD THERAPEUTICS INC
$16
Regeneron Healthcare Solutions, Inc.
$15
Top 3 companies account for 28.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$933
Genentech USA, Inc.
$489
Takeda Pharmaceuticals U.S.A., Inc.
$424
GENZYME CORPORATION
$361
Amgen Inc.
$329
E.R. Squibb & Sons, L.L.C.
$326
Astellas Pharma US Inc
$317
Celgene Corporation
$315
Daiichi Sankyo Inc.
$302
PFIZER INC.
$292
Gilead Sciences, Inc.
$280
ABBVIE INC.
$220
Janssen Biotech, Inc.
$192
Eisai Inc.
$167
Merck Sharp & Dohme LLC
$161
JAZZ PHARMACEUTICALS INC.
$151
Mylan Institutional Inc.
$150
Exelixis Inc.
$133
Sobi, Inc
$120
PharmaEssentia USA Corporation
$113
BeiGene USA, Inc.
$110
Janssen Pharmaceuticals, Inc
$109
SANOFI-AVENTIS U.S. LLC
$98
AstraZeneca Pharmaceuticals LP
$92
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$87
Regeneron Healthcare Solutions, Inc.
$85
Kite Pharma, Inc.
$82
Seagen Inc.
$81
Incyte Corporation
$81
TAIHO ONCOLOGY, INC.
$67
Tempus AI, Inc
$64
ADC Therapeutics America, Inc.
$63
SOBI, INC
$63
EMD Serono, Inc.
$63
TerSera Therapeutics LLC
$56
GlaxoSmithKline, LLC.
$55
AMAG Pharmaceuticals, Inc.
$51
AVEO Pharmaceuticals, Inc.
$49
Stemline Therapeutics Inc.
$46
Lilly USA, LLC
$41
Pharmacosmos Therapeutics Inc.
$41
Pharmacyclics LLC, An AbbVie Company
$40
EISAI INC.
$39
Pharmacyclics LLC, an AbbVie Company
$34
Octapharma USA, Inc.
$33
Taiho Oncology, Inc.
$32
Rigel Pharmaceuticals, Inc.
$27
RECORDATI_RARE_DISEASES_INC.
$26
Biocon Biologics Inc
$24
Karyopharm Therapeutics Inc.
$24
Bayer Healthcare Pharmaceuticals Inc.
$20
ARRAY BIOPHARMA INC
$18
Dova Pharmaceuticals
$18
Mirati Therapeutics, Inc.
$18
Foundation Medicine, Inc.
$17
Dendreon Pharmaceuticals LLC
$16
SHIELD THERAPEUTICS INC
$16
SERVIER PHARMACEUTICALS LLC
$14
PUMA BIOTECHNOLOGY, INC.
$11
Top 3 companies account for 24.0% of all-time payments
Associated products mentioned in payments ›
ABECMA · ACCRUFER · ANDEXXA · AUGTYRO · Alecensa · BAVENCIO · BESREMI · BRAFTOVI · BRUKINSA · Blincyto · CABOMETYX · CARVYKTI · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELITEK · ENHERTU · ENJAYMO · EPKINLY · Enhertu · FERAHEME · FOTIVDA · FOUNDATIONONE CDX · FRUZAQLA · FULPHILA · Fabhalta · GAZYVA · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · Lenvima · LifeVest · Lunsumio · MEKINIST · Monoferric · NERLYNX · NINLARO · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · Ogivri · Orserdu · PADCEV · PANZYGA · PLUVICTO · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · REBLOZYL · RYBREVANT · SARCLISA · SCEMBLIX · SYLVANT · TASIGNA · TECVAYLI · TUKYSA · Tavalisse · Tibsovo · Trodelvy · VENCLEXTA · VERZENIO · Vanflyta · Venclexta · XARELTO · XPOVIO · XTANDI · Xtandi · Yescarta · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (85%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a medical oncology specialist in Dearborn?
Compare medical oncologists in the Dearborn area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
58
Per 100K population
3.3
County median income
$59,521
Nearest hospital
BEAUMONT HOSPITAL - DEARBORN
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Khan is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Khan experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Khan performed 1,234 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khan receive payments from pharmaceutical companies?
Yes. Dr. Khan received a total of $7,686 from 59 companies across 353 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khan's costs compare to other medical oncologists in Dearborn?
Dr. Khan's average Medicare payment per service is $88. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →